1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
CA 2471880 A1 · Owner: Bayer Pharmaceuticals Corporation · Inventors: Baryza, Jeremy L.; Smith, Roger; Ladouceur, Gaetan H.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are pyrazolyl derivative compounds or purified stereoisomers or stereoisomer mixtures of said compounds and their salts or prodrug forms thereof which have structural formula (I) or (II): wherein the variables R R1, R2, R5 and R6 are as defined in the specification. The compounds are useful for the treatment or prevention of diseases and/or behaviors involving the 5-HT2C receptor .
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 28, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 28, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 28, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.